ConductScience.org, home

Paper42426348

Reversible and irreversible BTK inhibition promotes stem-like functional multipotency, persistence, and antitumor efficacy of CD19-directed CAR T cells in mantle cell lymphoma.

Yao Y and 6 others. Leukemia, 2026. Cited by 0 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Reversible and irreversible BTK inhibition promotes stem-like functional multipotency, persistence, and antitumor efficacy of CD19-directed CAR T cells in mantle cell lymphoma. Papers, record 42426348. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42426348

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Reversible and irreversible BTK inhibition promotes stem-like functional multipotency, persistence, and antitumor efficacy of CD19-directed CAR T cells in mantle cell lymphoma.
PubMed
Journal
Leukemia
PubMed
Year
2026
PubMed
Publication types
Letter
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-28
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Yao YYixinhttps://orcid.org/0000-0002-8439-6043
2Fei YYue
3Yan FFangfanghttps://orcid.org/0000-0001-6231-5225
4Li XXiaolin
5McIntosh JJoseph
6Liu YYanghttps://orcid.org/0000-0002-1910-8076
7Wang MMichaelhttps://orcid.org/0000-0001-9748-5486

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
AWD00008424Janssen Research and Development (Janssen R&D)PubMed

Source PubMed

Download CSV of grants

References14

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133932067Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma.Cancer Sci2021https://conductscience.org/library/papers/33932067PubMed
237883795CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study.Blood2024https://conductscience.org/library/papers/37883795PubMed
333230330MEK inhibition reprograms CD8+ T lymphocytes into memory stem cells with potent antitumor effects.Nat Immunol2021https://conductscience.org/library/papers/33230330PubMed
435596920BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma-Finding a Dancing Partner.Curr Oncol Rep2022https://conductscience.org/library/papers/35596920PubMed
535561314Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma.Blood Adv2022https://conductscience.org/library/papers/35561314PubMed
636086817Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies.Mol Ther2023https://conductscience.org/library/papers/36086817PubMed
739779871A multi-kinase inhibitor screen identifies inhibitors preserving stem-cell-like chimeric antigen receptor T cells.Nat Immunol2025https://conductscience.org/library/papers/39779871PubMed
836416874CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma.Cancer Discov2023https://conductscience.org/library/papers/36416874PubMed
928348046B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy.Clin Cancer Res2017https://conductscience.org/library/papers/28348046PubMed
1031586074Genetic modification of primary human B cells to model high-grade lymphoma.Nat Commun2019https://conductscience.org/library/papers/31586074PubMed
1131270272The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells.Sci Transl Med2019https://conductscience.org/library/papers/31270272PubMed
1237192437Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma.J Clin Oncol2023https://conductscience.org/library/papers/37192437PubMed
1326819453The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma.Clin Cancer Res2016https://conductscience.org/library/papers/26819453PubMed
1436796019Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor.Blood2023https://conductscience.org/library/papers/36796019PubMed

Download CSV of references

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
BTK695PubTator's text mininghttps://conductscience.org/library/genes/695NCBI Gene
CD19930PubTator's text mininghttps://conductscience.org/library/genes/930NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42426348

GET https://conductscience.org/api/papers/v1/42426348/authors